Introduction
Clinically significant portal hypertension (CSPH) in patients with advanced chronic liver disease (ACLD) is associated with increasing risk of decompensation and death. Several scores have been developed as non-invasive tests to assess portal hypertension (PH) severity, such as the novel hepatic venous pressure gradient (HVPG) score. This score, consisting of platelet count, total serum bilirubin, and international normalized ratio (INR), showed good sensibility in the prediction of severe PH.
Aims & Methods
The aim of this study is to evaluate the ability of HVPG score in the detection of PH in a cohort of patients with ACLD.
A retrospective study was conducted at the University of Naples and all patients, referred to our Liver Unit from 2012 to 2022, with compensated ACLD who underwent esophagogastroduodenoscopy (EGD) for portal hypertension assessment were enrolled. Exclusion criteria were patients < 18 years old, liver transplantation, treatment with NSBB, portal vein thrombosis and incomplete data. Clinical, biochemical, and imaging data were collected from medical records. Patients were stratified according to the presence of endoscopic signs of PH.
Results
Among 294 compensated ACLD patients who performed EGD, 204 subjects were enrolled (62.7% males, mean age 62 years) according to inclusion and exclusion criteria. The main etiologies of liver disease were HCV (39.2%), MAFLD (13.7%) and HBV (11.7%). One-hundred-eight patients (52.9%) showed endoscopic signs of PH (91 patients with esophageal varices, 13 subjects with gastric varices and 64 patients with portal hypertensive gastropathy). Patients with endoscopic signs of PH have higher HVPG score (14.14±1.62 vs 12.71±5.2 mmHg, p <0.001), higher spleen diameter (150±30.55 Vs 130±20.84 mm, p <0.001), lower platelet count (95*103/cc vs 136*103/cc, p<0.001) and lower platelets/spleen diameter ratio (682±397 vs 1090±604, p <0.01) than patients without signs of PH. Instead, liver stiffness was not different between the two groups (26±13.1 vs 23.7±9.96 kPa, p =0.233).
Among patients with endoscopic signs of PH, 11 (10.1%) patients experienced variceal bleeding after a mean of 29 months (range 124-2746 days); they had higher baseline HVPG score (14.82±0.93 vs 14.07±1.66 mmHg; p=0.04), higher spleen diameter (172±26.10 vs 150±30.23 mm; p=0.028) and lower PLT/spleen ratio (436±172 vs 710±405; p < 0.001) than patients who didn’t experience bleeding.
Conclusion
HVPG score is a simple tool for non-invasive prediction of PH and could be used to stratify the risk of bleeding in patients with ACLD. However, this score needs to be validated in larger cohorts.
References
Reiniš, J., Petrenko, O., Simbrunner, B., Hofer, B. S., Schepis, F., Scoppettuolo, M., ... & Reiberger, T. (2023). Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. Journal of Hepatology, 78(2), 390-400. DOI: 10.1016/j.jhep.2022.09.012